Qishenyiqi dripping pills: Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months
Placebo: Placebo, 1 bag once, three times a day, 12 months
Study summary
The effects of Qishenyiqi dripping pill on cardiac remodeling in patients with chronic stable heart failure have not been reported. This project aims to clarify the efficacy and safety of Qishenyiqi in patients with chronic heart failure after myocardial infarction. Patients with chronic stable heart failure after myocardial infarction were selected and randomly divided into two groups: the treatment group was treated with Qishenyiqi dripping pills; The control group was given placebo treatment. After 12 months of follow-up, the effects of Qishenyiqi on cardiac remodeling and function and cardiovascular adverse events were evaluated. The results are helpful to provide a new treatment strategy for chronic heart failure.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* 1\) The history of acute myocardial infarction exceeds 3 months;
* 2\) Symptoms and signs of heart failure have been stable for more than one month;
* 3\) 18 years old or more;
* 4\) NYHA cardiac function classified as grade II\~IV;
* 5\) LVEF≤40%；
* 6\) NT-proBNP≥450pg/ml；
* 7\) All subjects or their guardians must sign the subject consent before entering the trial.
Exclusion Criteria:
* 1\) Patients with the following diseases: nonischemic cardiomyopathy; valvular heart disease; congenital heart disease; obstruction of left ventricular outflow tract; severe decompensated heart failure; active myocarditis or pericardial disease; end-stage liver and kidney diseases; malignant tumor;
* 2\) Planned to undergo cardiac surgery within 12 months;
* 3\) Mechanical complications of myocardial infarction;
* 4\) Pregnant or nursing, or having the intention to give birth within one year;
* 5\) Patients who participated in clinical research of other drugs within 3 months before being selected;
* 6\) Patients with poor sound transmission windows are examined by transthoracic ultrasound.
Primary outcome measure(s)
LVEDVI=LVEDV/BSA — From baseline to 12 months after follow-up Changes of left ventricular end-diastolic volume index (LVEDVI) compared with baseline after 12 months
Trial sites (3)
Facility
City
Region
Status
Panpan Hao
Jinan
Shandong
Qianfoshan Hospital, Shandong University
Jinan
Shandong
Jinan Central Hospital Affiliated to Shandong First Medical University
Jinan
China
More Qilu Hospital of Shandong University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.